For the quarter ended March 2025, Baxter International (BAX) reported revenue of $2.63 billion, down 26.9% over the same period last year. EPS came in at $0.62, compared to $0.65 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $2.57 billion, representing a surprise of +2.09%. The company delivered an EPS surprise of +29.17%, with the consensus EPS estimate being $0.48.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Advanced Surgery- International: $123 million versus the three-analyst average estimate of $117.52 million. The reported number represents a year-over-year change of +6%.
- Net Sales- Pharmaceuticals- U.S. $195 million compared to the $196.51 million average estimate based on three analysts. The reported number represents a change of +2.1% year over year.
- Net Sales- Front Line Care- International: $75 million compared to the $69.14 million average estimate based on three analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- Other- U.S. $48 million versus $15.59 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +336.4% change.
- Net Sales- Pharmaceuticals: $581 million versus the four-analyst average estimate of $590.04 million. The reported number represents a year-over-year change of +0.5%.
- Net Sales- Other: $78 million versus the four-analyst average estimate of $46.71 million. The reported number represents a year-over-year change of +387.5%.
- Net Sales- Front Line Care: $277 million versus $269.11 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.5% change.
- Net Sales- Infusion Therapies and Technologies: $994 million versus $975.62 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.9% change.
- Net Sales- Care and Connectivity Solutions: $427 million versus $416.60 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
- Net Sales- Healthcare Systems and Technologies: $704 million versus $685.71 million estimated by four analysts on average.
- Net Sales- Medical Products and Therapies: $1.26 billion versus $1.25 billion estimated by four analysts on average.
- Net Sales- Injectables and Anesthesia: $335 million versus the three-analyst average estimate of $330.83 million.
View all Key Company Metrics for Baxter here>>>
Shares of Baxter have returned -7.4% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
